United Kingdom Gene Silencing Market Size, Share, and COVID-19 Impact Analysis, By Type (Product, and Service), By Application (Drug Discovery & Development, Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Others, Therapeutics Manufacturing, Agricultural Applications, and Others), and United Kingdom Gene Silencing Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Gene Silencing Market Insights Forecasts to 2035

• The United Kingdom Gene Silencing Market Size was Estimated at USD 600.25 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 14.8% from 2025 to 2035
• The United Kingdom Gene Silencing Market Size is Expected to Reach USD 2738.56 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the United Kingdom Gene Silencing Market Size is Anticipated to Reach USD 2738.56 Million by 2035, Growing at a CAGR of 14.8% from 2025 to 2035. The growing incidence of genetic abnormalities and chronic diseases, which has increased demand for targeted therapeutics like RNA interference (RNAi) and antisense oligonucleotides (ASOs), is driving the gene silencing sector.

Market Overview

The UK electrodeposited copper foils market refers to the business that supports healthcare by focusing on the deactivation of particular genes at the transcriptional or translational levels, or even throughout broader chromosomal areas. Inhibiting or "silencing" specific genes linked to different medical disorders is a contemporary therapeutic strategy that uses the body's natural processes to fight diseases. Gene silencing has potential as a treatment approach for several illnesses, including immune system abnormalities, infectious diseases, and cancer. This method seeks to lessen the underlying biological pathways causing pathology by focusing on particular genes that cause disease appearance. The discovery of genetic targets specific to disease is being improved by advances in genome sequencing and analytics. Gene silencing is being used by pharmaceutical corporations to create individualized treatment plans that minimize side effects and improve patient outcomes. This pattern is encouraging a paradigm change in the direction of tailored treatment approaches for various disease domains. The combination of this accuracy and developments in delivery methods, like lipid nanoparticles and exosomes, has greatly enhanced the therapeutic potential and safety profiles.

Report Coverage

This research report categorizes the market for the United Kingdom gene silencing market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom gene silencing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom gene silencing market.

Driving Factors

The market for United Kingdom gene silencing is driven by the country's healthcare sector industry's explosive growth and the significant investments made by top local and international technology companies in next-generation technology. The increasing need for tailored medicines to address uncommon and hereditary illnesses, where traditional medications have limited efficacy, is driving the UK gene silencing industry. Additionally, the UK has a robust biotech and academic ecosystem, with top universities like Oxford and Cambridge as well as government-supported programs like Innovate UK and the RNA Centre of Excellence at CPI promoting research and commercialization. More public and private sector investment, combined with a supportive environment for intellectual property, accelerates this market growth.

Restraining Factors

Despite substantial growth, some obstacles limit market expansion, notably the difficulty of obtaining regulatory permission and ensuring the scalability of manufacturing for RNA-based treatments, such as siRNA and antisense oligonucleotides (ASOs). The developing, new biotech companies face obstacles such as a lack of domestic infrastructure for RNA manufacturing, high R&D costs, and the possibility of unintended consequences exacerbating.

Market Segmentation

The United Kingdom gene silencing market share is classified into type, and application.

• The product segment held the highest share in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.

The United Kingdom gene silencing market is segmented by type into product, and service. Among these, the product segment held the highest share in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. This segment growth is driven by the stability, specificity, and efficacy of these therapies have been improved by innovations in delivery systems like lipid nanoparticles, GalNAc conjugates, and viral vectors. Additionally, the growing need for targeted treatment options for rare genetic disorders, cancer, and neurodegenerative diseases has sparked product development, and companies are actively investing in expanding their product pipelines.

• The drug discovery & development segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.

The United Kingdom gene silencing market is divided by application into drug discovery & development, neurology, oncology, infectious diseases, metabolic diseases, therapeutics manufacturing, agricultural applications, and others. Among these, the drug discovery & development segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. This is because partnerships among biotech businesses, academic institutions, and pharmaceutical corporations encourage innovation in drug discovery based on gene silencing, facilitating a quicker transition from preclinical research to clinical trials and propelling the expansion of the gene silencing industry.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom gene silencing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Silence Therapeutics
• MiNA Therapeutics
• SynaptixBio
• Oxford Biomedica
• Evox Therapeutics
• Storm Therapeutics
• CPI (RNA Centre of Excellence)
• Others

Recent Developments:

• In June 2025, Laverock Therapeutics, a UK-based biotech company that pioneered gene silencing technologies, expanded its seed funding round to over £20 million. This injection of capital fueled the development of its next-generation programmable therapies, aimed at treating conditions such as solid tumors and Type I diabetes. The funding round included major players like Eli Lilly, Mercia Ventures, and Calculus Capital, with new investor Norcliffe Capital joining the round.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom gene silencing market based on the below-mentioned segments:

United Kingdom Gene Silencing Market, By Type

• Product
• Service

United Kingdom Gene Silencing Market, By Application

• Drug Discovery & Development
• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Therapeutics Manufacturing
• Agricultural Applications
• Others